Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide–Based Vaccine in Patients With Refractory Advanced Non–Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide–Based Vaccine in Patients With Refractory Advanced Non–Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
American Society of Clinical Oncology (ASCO)
Online
2022-09-08
DOI
10.1200/jco.22.00096
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
- (2022) Espen Basmo Ellingsen et al. Journal for ImmunoTherapy of Cancer
- Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer
- (2021) Margaux Saillard et al. Vaccines
- Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma
- (2021) Charlée Nardin et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Challenges of Immunotherapy in Stage IV Non–Small-Cell Lung Cancer
- (2021) Sophie Stock-Martineau et al. JCO Oncology Practice
- IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
- (2021) O. Molinier et al. ESMO Open
- Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial
- (2020) Cesare Gridelli et al. BRITISH JOURNAL OF CANCER
- Anti-cancer Immunotherapies Targeting Telomerase
- (2020) Simone Negrini et al. Cancers
- Telomerase and CD4 T Cell Immunity in Cancer
- (2020) Magalie Dosset et al. Cancers
- Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials
- (2020) Laurie Spehner et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A Bayesian nonparametric causal inference model for synthesizing randomized clinical trial and real‐world evidence
- (2019) Chenguang Wang et al. STATISTICS IN MEDICINE
- Telomeres and telomerase: three decades of progress
- (2019) Jerry W. Shay et al. NATURE REVIEWS GENETICS
- Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
- (2019) Deborah B Doroshow et al. CLINICAL CANCER RESEARCH
- Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer
- (2019) Caroline Laheurte et al. BRITISH JOURNAL OF CANCER
- A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
- (2019) Luis Teixeira et al. CLINICAL CANCER RESEARCH
- Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
- (2019) Scott J Antonia et al. LANCET ONCOLOGY
- Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study
- (2018) Stefano Kim et al. LANCET ONCOLOGY
- Personalized vaccines for cancer immunotherapy
- (2018) Ugur Sahin et al. SCIENCE
- Correlates of immune and clinical activity of novel cancer vaccines
- (2018) Sjoerd H. van der Burg SEMINARS IN IMMUNOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- CD4 + T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness
- (2017) Tomasz Ahrends et al. IMMUNITY
- The immune contexture in cancer prognosis and treatment
- (2017) Wolf H. Fridman et al. Nature Reviews Clinical Oncology
- Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells
- (2016) Jeanne Galaine et al. JOURNAL OF IMMUNOLOGY
- A second chance for telomerase reverse transcriptase in anticancer immunotherapy
- (2016) Maurizio Zanetti Nature Reviews Clinical Oncology
- The Human Vaccines Project: A roadmap for cancer vaccine development
- (2016) Pedro Romero et al. Science Translational Medicine
- A Bayesian adaptive phase I-II trial design for optimizing the schedule of therapeutic cancer vaccines
- (2016) Kristen M. Cunanan et al. STATISTICS IN MEDICINE
- Role of Telomeres and Telomerase in Aging and Cancer
- (2016) J. W. Shay Cancer Discovery
- CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful
- (2014) H.-J. Kim et al. Cancer Immunology Research
- A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)
- (2013) C. L. Slingluff et al. CLINICAL CANCER RESEARCH
- Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination
- (2013) Magalie Dosset et al. OncoImmunology
- Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
- (2012) M. Dosset et al. CLINICAL CANCER RESEARCH
- Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response
- (2012) Y. Godet et al. CLINICAL CANCER RESEARCH
- Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001
- (2012) Else-Marit Inderberg-Suso et al. OncoImmunology
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine
- (2011) Craig L. Slingluff et al. JOURNAL OF CLINICAL ONCOLOGY
- Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas
- (2010) Sarah Zohar et al. PHARMACEUTICAL STATISTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now